Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD

This trial investigates whether elderly veterans who have both obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD) — a combination called 'Overlap Syndrome' — suffer worse cognitive impairment than veterans who have either disease alone. Repeated cycles of low oxygen during sleep are thought to damage brain circuits involved in memory and executive function, and having two conditions that each independently reduce oxygen delivery may compound that harm. The study also tests whether treating the Overlap Syndrome more aggressively — with positive airway pressure (PAP) plus supplemental oxygen — produces better cognitive and quality-of-life outcomes than PAP alone. Recruiting through the VA system, it focuses on an older population where both COPD and OSA are highly prevalent and where cognitive decline carries heavy personal and healthcare system costs. If the combined-treatment arm outperforms PAP alone, it would justify a more intensive standard of care for this specific dual-diagnosis group. The trial is currently recruiting, with an estimated completion date in mid-2026, so no results are yet available. Its importance lies in addressing a mechanistically plausible but empirically under-tested synergy between two of the most common chronic diseases seen in aging veterans.

• No results available yet — the trial is actively recruiting as of its latest ClinicalTrials.gov update (status: RECRUITING, estimated completion 2026-05-26).
• The study's primary hypothesis is that Overlap Syndrome (OSA + COPD) produces greater cognitive deficits than either OSA alone or COPD alone, reflecting an additive or synergistic hypoxemia burden.
• The intervention comparison — PAP + supplemental oxygen versus PAP alone — is designed to test whether correcting both the obstructive and the hypoxemic components of Overlap Syndrome is necessary to achieve neurocognitive and quality-of-life benefit.

This is a randomized controlled trial (NCT02703207) conducted within the Veterans Health Administration, enrolling elderly veterans who carry a diagnosis of both OSA and COPD (Overlap Syndrome), with comparator arms of OSA-only and COPD-only participants. The intervention arm randomizes Overlap Syndrome participants to PAP plus supplemental oxygen versus PAP alone, with neurocognitive function and health-related quality of life as key outcome domains. Follow-up duration is not specified in the available abstract but the trial's estimated primary completion is May 2026. Sample size and specific cognitive battery details are not reported in the publicly available abstract; confidence in these methodological details is accordingly limited.

Because the trial is still recruiting, no efficacy or safety data are available and all findings described here are hypothesized outcomes rather than empirical results. The VA-based, predominantly male, elderly veteran sample limits generalizability to women, younger adults, and civilian populations with different comorbidity profiles. The study cannot determine whether cognitive improvements, if observed, reflect reversal of existing neuronal injury or merely functional compensation during treatment, nor can it resolve the long-term durability of any benefit after treatment cessation. A next logical experiment would be a longer follow-up study (3–5 years) examining whether sustained combined PAP-plus-oxygen therapy reduces incident dementia rates in this population.

This trial sits at the intersection of sleep-disordered breathing, intermittent hypoxia, and cognitive aging, directly extending the mechanistic questions raised by [§110], which examines how intermittent hypoxia alters respiratory loop gain in healthy subjects — a pathophysiological upstream process that likely operates with even greater severity in veterans whose COPD already compromises baseline oxygenation. It parallels [§95] (the OSADA trial on OSA and difficult asthma), which similarly tests whether treating comorbid airway disease alongside OSA improves outcomes beyond OSA treatment alone, though OSADA targets a different organ-level endpoint. The cognitive impairment focus also parallels [§33], which investigates time-restricted eating as a lifestyle intervention for Alzheimer's disease risk, since both studies probe whether a modifiable physiological stressor (hypoxemia here, metabolic dysregulation there) is a tractable upstream target for preventing dementia in older adults. Finally, the glymphatic-clearance literature represented by [§43] provides a plausible cellular mechanism linking OSA-related hypoxia and sleep fragmentation to the cognitive deficits this trial aims to quantify and reverse.

• Influence of Intermittent Hypoxia on Loop Gain in Healthy Subjects
  Directly relevant upstream mechanism: [id=110] quantifies how intermittent hypoxia reshapes ventilatory control (loop gain), the same hypoxemic insult that the Overlap Syndrome trial hypothesizes drives cognitive injury when OSA and COPD co-occur.
• Obstructive Sleep Apnoea and Difficult Asthma (OSADA)
  Near-parallel RCT design testing whether treating a second airway comorbidity (asthma in OSADA vs. COPD here) on top of OSA management improves outcomes beyond OSA treatment alone — comparing results will help disentangle OSA-specific versus general airway-disease effects.
• Association between obstructive sleep apnea severity and glymphatic-related DTI-ALPS alterations in newly diagnosed, Drug-Naïve Alzheimer's disease
  Provides a candidate biological mechanism (impaired glymphatic clearance indexed by DTI-ALPS) for the cognitive deficits the Overlap Syndrome trial aims to measure, linking OSA severity to brain waste-clearance failure.
• TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
  Shares the goal of attenuating dementia risk in older adults via a non-pharmacological intervention, allowing comparison of magnitude and durability of cognitive benefit across very different mechanistic entry points (hypoxemia correction vs. metabolic time-restriction).
• Population Based Lighting Study on Older Adults
  Also an intervention RCT in older adults targeting a modifiable environmental/physiological exposure (light environment) to improve brain and circadian health, offering a useful methodological benchmark for recruitment, retention, and cognitive outcome measurement in aging veteran-adjacent populations.